Journals / art / 2016 / Cilt: 31 - Sayı: 4

Different Therapeutic Paths (Colchicine vs. Anakinra) in Two Patients With Schnitzler's Syndrome

Journal
art
Pages
377–380
DOI
—
🏛️Bibliographic metadata and full text access for this article are provided via DergiPark.
DergiPark Record ↗
✨

AI Summary & Key Takeaways

AI Insight
⚡ TL;DR(Too Long; Didn't Read)

Further studies are needed to determine the precise mechanism of disease and the appropriate targeted therapy.

📌 3 Key Takeaways

🎯
Objective & Hypothesis:Schnitzler's syndrome is a rare autoinflammatory syndrome with unidentified mechanism of disease and etiology with unknown definitive treatment algorithm.
📊
Key Findings & Data:In this article, we describe two patients with different courses of disease with different average lengths of time between initial symptoms and the final diagnosis (6 months to 8 years).
💡
Conclusion & Impact:Further studies are needed to determine the precise mechanism of disease and the appropriate targeted therapy.
🔬Design:Research Article
📍Scope:Comprehensive Sample
⚙️Variables:Domain Parameters

Abstract

Schnitzler's syndrome is a rare autoinflammatory syndrome with unidentified mechanism of disease and etiology with unknown definitive treatment algorithm. The two obligatory criteria for the diagnosis of Schnitzler's syndrome include chronic urticarial rash and monoclonal gammopathy (immunoglobulin M or immunoglobulin G). In this article, we describe two patients with different courses of disease with different average lengths of time between initial symptoms and the final diagnosis (6 months to 8 years). Exclusion of more common conditions is needed to ensure the correct diagnosis. Treatment strategy depends on the patient's constitutional symptoms (fever, malaise, generalized myalgia, and arthralgias) and laboratory tests of inflammation. Treatment includes usage of conventional drugs and cytokine blockade (interleukin-1 and interleukin-6). Further studies are needed to determine the precise mechanism of disease and the appropriate targeted therapy.

🔖

Cite This Article

BARESIC, M., MITROVI?, J., MOROVI?, J. V., ANIC, B. (2016). Different Therapeutic Paths (Colchicine vs. Anakinra) in Two Patients With Schnitzler's Syndrome. art, Cilt: 31 - Sayı: 4, 377–380. https://ajindex.com/articles/178190

📄 Full Text PDF Viewer

📄

PDF görüntüleyici hazırlanıyor...

References (6)

  1. Schnitzler L: Lésions urticariennes chroniques permanentes (érythème pétaloïde?). J Dermatol Angers; 1972.
  2. Simon A, Asli B, Braun-Falco M, De Koning H, Fermand JP, Grattan C, et al. Schnitzler's syndrome: diagnosis, treatment, and follow-up. Allergy 2013;68:562-8. Lipsker D. The Schnitzler syndrome. Orphanet J Rare Dis 2010;5:38. Markotic A, Skerk V, Cvetko Krajinovic L, Beus A. Is the clinical picture of Schnitzler syndrome always Schnitzler syndrome? Clin Exp Rheumatol 2009;27:507-9.
  3. Sokumbi O, Drage LA, Peters MS. Clinical and histopathologic review of Schnitzler syndrome: the Mayo Clinic experience (1972-2011). J Am Acad Dermatol 2012;67:1289-95.
  4. Tinazzi E, Puccetti A, Patuzzo G, Sorleto M, Barbieri A, Lunardi C. Schnitzler syndrome, an autoimmune- autoinflammatory syndrome: report of two new cases and review of the literature. Autoimmun Rev 2011;10:404-9.
  5. Koch A, Tchernev G, Chokoeva AA, Lotti T, Wollina U. Schnitzler syndrome responding to interleukin-1 antagonist anakinra. J Biol Regul Homeost Agents 2015;29(1 Suppl):19-21.
  6. Besada E, Nossent H. Dramatic response to IL1- RA treatment in longstanding multidrug resistant Schnitzler's syndrome: a case report and literature review. Clin Rheumatol 2010;29:567-71. Néel A, Henry B, Barbarot S, Masseau A, Perrin F, Bernier C, et al. Long-term effectiveness and safety of interleukin-1 receptor antagonist (anakinra) in Schnitzler's syndrome: a French multicenter study. Autoimmun Rev 2014;13:1035-41. de Koning HD, Schalkwijk J, Stoffels M, Jongekrijg J, Jacobs JF, Verwiel E, et al. The role of interleukin-1 beta in the pathophysiology of Schnitzler's syndrome. Arthritis Res Ther 2015;17:187. Krause K, Feist E, Fiene M, Kallinich T, Maurer M. Complete remission in 3 of 3 anti-IL-6-treated patients with Schnitzler syndrome. J Allergy Clin Immunol 2012;129:848-50. de Koning HD. Schnitzler's syndrome: lessons from 281 cases. Clin Transl Allergy 2014;4:41.